Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oxford Immunotec

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

BMJ to only publish trials with open data

Comes as journal pushes Roche for full data on Tamiflu

Roche - Basel

EMA launches probe into Roche’s adverse event reporting

Pharma company allegedly failed to follow pharmacovigilance procedures

Roche - Basel

Roche Q3 sales up on cancer drugs

And CEO Schwan commits to gene sequencing despite failed Illumina bid

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

Roche: Scotland must improve cancer drug access

Pharma company's call comes as SMC decides not to recommend Avastin in ovarian cancer

Roche - Basel

Roche’s T-DM1 activity in breast cancer “outstanding”

Improves survival by six months compared to GSK’s Tykerb/Tyverb

- PMLiVE

Roche plans translational research centre in New York

Follows plan to close New Jersey headquarters

- PMLiVE

Roche loses Indian Tarceva patent battle with Cipla

As Novartis' Glivec patent law challenge begins again

Roche - Basel

Roche says pipeline will balance cancer drug patent losses

Has 11 new molecular entities in late-stage portfolio and 11 line extensions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links